CoRISMA MCS Systems

Executive Summary

CoRISMA MCS Systems is a private medical device company pioneering non-invasive, continuous hemodynamic monitoring for critical care and perioperative settings. Its core technology, the CoRISMA Multi-Channel System (MCS), addresses the need for real-time, accurate assessment of cardiovascular status in patients with or at risk of cardiogenic shock—a condition associated with high mortality and challenging fluid and inotropic management. By providing clinicians with continuous, non-invasive hemodynamic data, CoRISMA aims to improve clinical decision-making, reduce complications, and potentially lower healthcare costs. The platform leverages advanced sensor technology and signal processing to deliver actionable insights without the risks of invasive catheters. CoRISMA targets a significant unmet need in the $X billion global hemodynamic monitoring market, which is dominated by invasive techniques. The company is based in San Diego, California, and has been developing its platform since 2010. While still in a pre-commercial stage, CoRISMA has the potential to disrupt critical care monitoring if it achieves regulatory clearances and clinical validation. The company's success hinges on demonstrating superior accuracy, ease of use, and clinical outcomes compared to existing non-invasive and minimally invasive alternatives. With increasing emphasis on early detection and personalized fluid management in shock, CoRISMA's technology could become a standard-of-care tool in intensive care units and operating rooms worldwide. However, as a private entity with limited public information, its valuation, funding, and revenue status remain undisclosed.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for CoRISMA MCS System70% success
• Q2 2027Presentation of Pivotal Clinical Trial Results Demonstrating Reduced Adverse Events in Cardiogenic Shock50% success
• Q3 2026Strategic Distribution or Co-Development Partnership with a Major Critical Care Company40% success